MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study

CY. Yu, WG. Liu, AP. Gong, LH. Shen, H. Huang, Y. Zhao, CF. Liu (nanjing, China)

Meeting: 2023 International Congress

Abstract Number: 148

Keywords: Dopamine receptor antagonists, Entacapone, Wearing-off fluctuations

Category: Parkinson’s Disease: Clinical Trials

Objective: This study aimed to investigate the efficacy and safety comparison between LCE and Pramexol in Chinese PD patients with the wearing-off phenomenon.

Background: Wearing off (WO) is often associated with long-term Levodopa therapy in patients with Parkinson’s Disease (PD). Entacapone and dopamine receptor agonists are recommended by International Parkinson and Movement Disorder Society (MDS) for PD patients with wearing-off. Stalevo is a compound dosage form of levodopa / carbidopa / entacapone (levodopa / carbidopa / entacapone, LCE).

Method: The study population was PD patients with wearing-off phenomena requiring ongoing treatment with stable levodopa (LD) at a dose of ≥ 300 mg / day and with a daily “off ” period for ≥ 1.5 hours. All patients had not taken entacapone or levodopa receptor agonists recently. During the screening period, patients were required to complete history taking, venous blood collection and assessment of relevant scales. After enrollment, they were randomly divided into an LD switch to LCE treatment group and an LD add-on pramexol group. The drug regimen adjustment period and drug stabilization period were 4 weeks each. At the end of the 8th week patients need to record the patient diary again for 3 days and complete the related examination and assessment for follow-up period.

Results: 76 patients ranged in age from 44 to 82 (mean 65.61±8.74), and the course of disease ranged from 1 to 22 years (mean 7.57±4.06). After randomization, 44 patients were assigned to the LCE group and 32 to the Pramexol group. There were no statistically significant differences in patients’ age, disease duration, and UPDRS (III) scores between the two groups. After the optimization of treatment regimen, the “on” period of patients in both groups was increased, with 2.11±1.73 hours in the LCE group and 1.62±2.07 hours in the pramexole group. At the same time, the “off” period of both groups was shortened, with 2.01±1.89 hours in the LCE group and 1.76±2.13 hours in the pramexole group.

Conclusion: For PD patients with wearing-off, the use of entacapone and dopamine receptor agonists can shorten the “off” period and prolong the “on” period of patients, which can improve the fluctuation of clinical symptoms of patients. The improvement degree of patients in the two groups is similar.

 1

 2

To cite this abstract in AMA style:

CY. Yu, WG. Liu, AP. Gong, LH. Shen, H. Huang, Y. Zhao, CF. Liu. Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/efficacy-of-levodopa-carbidopa-entacapone-replacement-of-levodopa-dopa-decarboxylase-inhibitors-in-treatment-of-chinese-parkinsons-disease-patients-with-wearing-off-a-multicenter-randomized-contro/. Accessed September 25, 2023.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-of-levodopa-carbidopa-entacapone-replacement-of-levodopa-dopa-decarboxylase-inhibitors-in-treatment-of-chinese-parkinsons-disease-patients-with-wearing-off-a-multicenter-randomized-contro/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23107 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley